

## REMARKS


New claims 35-89 have been presented. Support for these claims resides throughout the specification, original claims, and Sequence Listing. See for example, at page 2, lines 14-16, page 3, lines 21-23, page 5, lines 21-25, and SEQ ID NOS: 9 and 10, describing biologically active interferons that contain a carboxy terminus truncation, and which comprise 157 or 158 amino acids; SEQ ID NO:9 and SEQ ID NO:10, setting forth the mature human  $\alpha$ -2b-interferon with a carboxy terminus truncation resulting in a polypeptide having 158 and 157 amino acid residues, respectively; SEQ ID NO:11 setting forth residues 1-157 and 1-158 of mature human  $\alpha$ -2b-interferon; at page 6, lines 1-10, describing polynucleotides encoding the claimed polypeptides, and expression cassettes comprising these polynucleotides; at page 11, line 30, continuing through page 12, line 23, describing these polypeptides comprising signal peptides and polynucleotides encoding these signal peptides operably linked to the sequence encoding the claimed polypeptides; at page 12, line 26, continuing through page 13, line 22, describing prokaryotic (including bacterial) and eukaryotic (including plant, mammal, and yeast) host cells for producing the claimed polypeptides; at page 14, line 1, continuing through page 15, line 25, describing pharmaceutical compositions comprising the claimed polypeptides, including those containing polyethylene glycol (page 14, line 15); and pages 16-17, describing expression vectors for expressing the claimed polypeptides. No new matter is added by way of presentation of these new claims.

The Examiner is respectfully requested to enter these new claims into the above-referenced application prior to substantive examination of this application on its merits.

Appl. No.: 10/574,046  
International Appl. No. PCT/US2004/011965  
International Filing Date: April 16, 2004  
Amdt. Dated January 31, 2007

It is not believed that additional fees for net addition of claims are necessary to allow consideration of this paper. However, any such additional fee required therefore is hereby authorized to be charged to Deposit Account No. 16-0605.

Respectfully submitted,



Leslie T. Henry  
Registration No. 45,714

**Customer No. 00826**  
**ALSTON & BIRD LLP**  
Bank of America Plaza  
101 South Tryon Street, Suite 4000  
Charlotte, NC 28280-4000  
Tel Raleigh Office (919) 862-2200  
Fax Raleigh Office (919) 862-2260

ELECTRONICALLY FILED USING THE EFS-WEB ELECTRONIC FILING SYSTEM OF THE UNITED STATES PATENT & TRADEMARK OFFICE ON January 31, 2007.

LEGAL02/30232657v1